Investors
This section contains information about Orion as an investment.
Stock exchange releases
- 10/29/2024 Orion Group Interim Report January–September 2024
- 10/24/2024 Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
- 9/20/2024 213,285 Orion Corporation A shares converted into B shares
- 9/11/2024 Inside information: Orion upgrades full-year outlook for 2024
Press releases
- 11/19/2024 Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
- 10/15/2024 Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024
- 10/14/2024 Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
- 9/30/2024 Orion’s near-term climate targets approved by the Science Based Targets initiative
